A photo of Alexei Grom.

Research Director, Division of Rheumatology

Professor, UC Department of Pediatrics

513-636-3339

513-636-3328

Board Certified

Make an Appointment

Visit the Grom-Thorton Research Lab

My Biography & Research

Biography

My early work with outstanding mentors, who were pediatric rheumatologists, led me to pursue my clinical and research interests. During my fellowship, the unfortunate death of a patient from macrophage activation syndrome (MAS) prompted me to further study this life-threatening complication of systemic juvenile idiopathic arthritis.

Currently, I focus on identifying risk factors and new therapeutic targets in MAS. Our transnational studies have identified interferon gamma (INF), a dimerized soluble cytokine, as a therapeutic target in patients suffering from MAS. This discovery provided the rationale for a new clinical trial that is currently underway.

My research is funded by the National Institutes of Health (NIH) and the Systemic Juvenile Idiopathic Arthritis (SJIA) Foundation. I have also received research grants from Sobi, Novartis and AB2Bio.

Additional Languages

French, Russian

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Rheumatology, Lupus, Rare Lung Diseases

Research Divisions

Rheumatology



Blog Posts

My Locations

My Education

MD: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1986.

Residency: Leningrad (St. Petersburg) Medical Institute, Russia, 1988; Children's Hospital Medical Center, Cincinnati, OH, 1998.

Fellowship: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1991; Children's Hospital Medical Center, Cincinnati, OH, 1995.

Certification: Pediatrics, 1999.

My Publications

Distinct gene expression signatures characterize strong clinical responders vs non-responders to Canakinumab in children with sJIA. Verweyen, EL; Pickering, A; Grom, AA; Schulert, GS. Arthritis and Rheumatology. 2021.

The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. Pediatric Rheumatology. 2020; 18.

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study. Locatelli, F; Jordan, MB; Allen, C; Cesaro, S; Rizzari, C; Rao, A; Degar, B; Garrington, T; Sevilla, J; Putti, MC; et al. Blood. 2020; 136:24-25.

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH). Locatelli, F; Jordan, MB; Allen, C; Cesaro, S; Rizzari, C; Rao, A; Degar, B; Garrington, T; Sevilla, J; Putti, MC; et al. Blood. 2020; 136:14-15.

A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). Lin, B; Berard, R; Al Rasheed, A; Aladba, B; Kranzusch, PJ; Henderlight, M; Grom, A; Kahle, D; Torreggiani, S; Aue, AG; et al. Journal of Allergy and Clinical Immunology. 2020; 146:1204-1208.e6.

Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Canna, SW; Schulert, GS; de Jesus, A; Pickering, A; Brunner, H; Gadina, M; Levine, S; Goldbach-Mansky, R; Boutelle, J; Sinha, R; et al. Pediatric Rheumatology. 2020; 18.

On the Alert for Cytokine Storm: Immunopathology in COVID-19. Henderson, LA; Canna, SW; Schulert, GS; Volpi, S; Lee, PY; Kernan, KF; Caricchio, R; Mahmud, S; Hazen, MM; Halyabar, O; et al. Arthritis and Rheumatology. 2020; 72:1059-1063.

S100 Proteins, Cytokines, and Chemokines as Tear Biomarkers in Children with Juvenile Idiopathic Arthritis-associated Uveitis. Angeles-Han, ST; Miraldi Utz, V; Thornton, S; Schulert, G; Rodriguez-Smith, J; Kauffman, A; Sproles, A; Mwase, N; Hennard, T; Grom, A; et al. Ocular Immunology and Inflammation. 2020; 1-5.

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. Locatelli, F; Jordan, MB; Allen, C; Cesaro, S; Rizzari, C; Rao, A; Degar, B; Garrington, TP; Sevilla, J; Putti, M; et al. New England Journal of Medicine. 2020; 382:1811-1822.

Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. de Jesus, AA; Hou, Y; Brooks, S; Malle, L; Biancotto, A; Huang, Y; Calvo, KR; Marrero, B; Moir, S; Oler, AJ; et al. Journal of Clinical Investigation. 2020; 130:1669-1682.